Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials
详细信息 查看全文
- 作者：Frank Tacke ; Rainer Gü ; nther ; Peter Buggisch ; Hartwig Klinker ; Andreas Schober ; Christine John ; Thomas Lutz ; Heike Pfeiffer-Vornkahl ; Claus Niederau ; Markus Cornberg ; Christoph Sarrazin and Stefan Mauss
- 刊名：Liver International
- 出版年：2017
- 出版时间：February 2017
- 年：2017
- 卷：37
- 期：2
- 页码：205-211
- 全文大小：372K
- ISSN：1478-3231
文摘
Hepatitis C virus (HCV) infections with genotype 2 (GT2) are generally considered as easy to treat. The current standard therapy is 12 weeks of sofosbuvir and ribavirin. However, sustained virological response (SVR) rates varied substantially in distinct subgroups. Therefore, re-assessing the efficacy of interferon-free therapy in cohorts with larger patient numbers is warranted.